Evidence supports a causal association between allele-specific vitamin D receptor binding and multiple sclerosis among Europeans
Open Access
- 12 February 2024
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (8)
Abstract
Although evidence exists for a causal association between 25-hydroxyvitamin D (25(OH)D) serum levels, and multiple sclerosis (MS), the role of variation in vitamin D receptor (VDR) binding in MS is unknown. Here, we leveraged previously identified variants associated with allele imbalance in VDR binding (VDR-binding variant; VDR-BV) in ChIP-exo data from calcitriol-stimulated lymphoblastoid cell lines and 25(OH)D serum levels from genome-wide association studies to construct genetic instrumental variables (GIVs). GIVs are composed of one or more genetic variants that serve as proxies for exposures of interest. Here, GIVs for both VDR-BVs and 25(OH)D were used in a two-sample Mendelian Randomization study to investigate the relationship between VDR binding at a locus, 25(OH)D serum levels, and MS risk. Data for 13,598 MS cases and 38,887 controls of European ancestry from Kaiser Permanente Northern California, Swedish MS studies, and the UK Biobank were included. We estimated the association between each VDR-BV GIV and MS. Significant interaction between a VDR-BV GIV and a GIV for serum 25OH(D) was evidence for a causal association between VDR-BVs and MS unbiased by pleiotropy. We observed evidence for associations between two VDR-BVs (rs2881514, rs2531804) and MS after correction for multiple tests. There was evidence of interaction between rs2881514 and a 25(OH)D GIV, providing evidence of a causal association between rs2881514 and MS. This study is the first to demonstrate evidence that variation in VDR binding at a locus contributes to MS risk. Our results are relevant to other autoimmune diseases in which vitamin D plays a role.Keywords
Funding Information
- HHS | National Institutes of Health (R01NS049510)
- HHS | National Institutes of Health (R01ES017080)
- HHS | National Institutes of Health (R01AI076544)
- National Multiple Sclerosis Society (RG-19707-34664)
- HHS | National Institutes of Health (RC2AG036607)
- UKRI | Medical Research Council (MC_UU_00007/15)
- Magareta af Ugglas foundation (NA)
- MultipleMS project EU Horizon 2020 (733161)
- Robert Wood Johnson Foundation (NA)
- Wayne and Gladys Valley Foundation (NA)
- The Ellison Medical Foundation (NA)
This publication has 39 references indexed in Scilit:
- Vitamin D and Multiple Sclerosis: A Comprehensive ReviewNeurology and Therapy, 2017
- Vitamin D Metabolism, Mechanism of Action, and Clinical ApplicationsChemistry & Biology, 2014
- Alcohol as a Modifiable Lifestyle Factor Affecting Multiple Sclerosis RiskJAMA Neurology, 2014
- Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosisAnnals of Neurology, 2012
- Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosisAnnals of Neurology, 2010
- Vitamin D and multiple sclerosisThe Lancet Neurology, 2010
- The Vitamin D Receptor: New Paradigms for the Regulation of Gene Expression by 1,25-Dihydroxyvitamin D3Endocrinology and Metabolism Clinics of North America, 2010
- Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic CircleJournal of Neurology, 2007
- Serum 25-Hydroxyvitamin D Levels and Risk of Multiple SclerosisJAMA, 2006
- The prevalence of multiple sclerosis in the world: an updateNeurological Sciences, 2001